Subject(s)
Malaria, Vivax/diagnosis , Medical Audit , Military Personnel , Afghan Campaign 2001- , Afghanistan , Animals , Antimalarials/therapeutic use , Cellulitis/complications , Cellulitis/diagnosis , Chloroquine/therapeutic use , Diagnosis, Differential , Humans , Malaria, Vivax/complications , Malaria, Vivax/drug therapy , Male , Narcotics/adverse effects , Opium/adverse effects , Sepsis/diagnosis , Sepsis/drug therapy , Sepsis/etiology , Substance Withdrawal Syndrome/diagnosis , Surveys and Questionnaires , United Kingdom , Young AdultABSTRACT
BACKGROUND: Sepsis results in significant morbidity and mortality, with current treatment options limited with respect to efficacy as well as safety. The complex homeopathic remedy Traumeel S has been shown to have both anti-inflammatory and immunostimulatory effects in the in vitro setting. OBJECTIVES: The objective was to explore the effects of Traumeel S in an in vivo setting, using a cecal ligation and puncture (CLP) sepsis model in rats, evaluating the effects of the medication on cytokine activity. DESIGN: Sepsis was induced in 30 rats using accepted CLP methodology. Following the procedure, rats were randomly allocated to receive an intraperitoneal injection of either Traumeel S (n=15) or normal saline (n=15). At 6 hours post-CLP, serum cytokines (interleukin [IL]-1ß, tumor necrosis factor-α, IL-6, and IL-10) were evaluated. RESULTS: IL-1ß levels were significantly higher in the treatment group (p=0.03) with no significant differences found between the groups with respect to the other cytokines tested. CONCLUSIONS: In contrast to in vitro studies, Traumeel significantly increased IL-1ß levels in an in vivo model, without influencing other cytokines. IL-1ß is a proinflammatory cytokine that has been shown to have a protective effect in the CLP rat model. Further research is warranted to examine this finding, as well as its clinical implications.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Homeopathy , Interleukin-1beta/blood , Minerals/therapeutic use , Plant Extracts/therapeutic use , Sepsis/drug therapy , Wounds and Injuries/drug therapy , Adjuvants, Immunologic/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Cecum , Disease Models, Animal , Ligation , Male , Minerals/pharmacology , Plant Extracts/pharmacology , Random Allocation , Rats , Rats, Sprague-Dawley , Sepsis/blood , Sepsis/etiology , Wounds and Injuries/blood , Wounds and Injuries/complicationsABSTRACT
BACKGROUND: Mortality in patients with severe sepsis remains high despite the development of several therapeutic strategies. The aim of this randomized, double-blind, placebo-controlled trial was to evaluate whether homeopathy is able to influence long-term outcome in critically ill patients suffering from severe sepsis. METHODS: Seventy patients with severe sepsis received homeopathic treatment (n = 35) or placebo (n = 35). Five globules in a potency of 200c were given at 12h interval during the stay at the intensive care unit. Survival after a 30 and 180 days was recorded. RESULTS: Three patients (2 homeopathy, 1 placebo) were excluded from the analyses because of incomplete data. All these patients survived. Baseline characteristics including age, sex, BMI, prior conditions, APACHE II score, signs of sepsis, number of organ failures, need for mechanical ventilation, need for vasopressors or veno-venous hemofiltration, and laboratory parameters were not significantly different between groups. On day 30, there was non-statistically significantly trend of survival in favour of homeopathy (verum 81.8%, placebo 67.7%, P= 0.19). On day 180, survival was statistically significantly higher with verum homeopathy (75.8% vs 50.0%, P = 0.043). No adverse effects were observed. CONCLUSIONS: Our data suggest that homeopathic treatment may be a useful additional therapeutic measure with a long-term benefit for severely septic patients admitted to the intensive care unit. A constraint to wider application of this method is the limited number of trained homeopaths.
Subject(s)
Homeopathy/methods , Sepsis/drug therapy , APACHE , Aged , Anti-Infective Agents/administration & dosage , Chemotherapy, Adjuvant , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Middle Aged , Pain Measurement/methods , Prospective Studies , Sepsis/physiopathology , Severity of Illness Index , Shock, Septic/drug therapy , Survival Analysis , Treatment OutcomeABSTRACT
A fatal case of fulminant hepatic failure that occurred in the neonatal period is reported in a premature infant born after 27 4/7-weeks' gestation. Immediately after birth the infant had severe hypoxia and hypotension resulting from birth asphyxia, hypovolemic shock, and septicemia. At autopsy, histological appearance of the liver showed virtually total hepatocellular necrosis without features of fibrosis. Although the exact cause of hepatocellular injury cannot be fully ascertained, it is assumed that hypoxia and hypotension must have been the predominant factors leading to massive hepatic necrosis.